Aditxt has filed a preliminary proxy statement seeking shareholder approval for employee stock purchase plan, company name change, and other proposals
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of...
Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a non-invasive alternative to surgical diagnosis for endometriosis
-- Evofem Shareholders Did Not Approve the Merger with Aditxt --
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...
-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI ® (lactic acid citric acid and potassium bitartrate) --
-- Special Meeting to be held on September 26, 2025 --
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026
-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives --
Crypto.com to Provide Custody Services for Proposed Aditxt Digital Asset Treasury